Cancer moonshot 2020 milestone: novel-novel combination of GPS Cancer guided cell based NK cell therapy and fusion proteins in QUILT trial CULVER CITY, Calif. & MIRAMAR, Fla. --(BUSINESS WIRE)--Oct. 4, 2016-- Altor BioScience Corporation (Altor), a leading developer of novel cytokine-based
SAN DIEGO --(BUSINESS WIRE)--Sep. 10, 2020-- Brink Biologics, Inc. (“Brink”), a NantKwest, Inc. (NASDAQ: NK) affiliate and exclusively-licensed distributor of NantKwest’s proprietary off-the-shelf NK-92® natural killer cells in certain fields, announces the licensing of its next-generation natural
NK-92® Cell Based Bioanalytical Solutions are the Key to Optimizing R&D and Commercial Product Development Efforts for Monoclonal Antibodies, Bi-Specifics and Related Biological Products SAN DIEGO --(BUSINESS WIRE)--May 1, 2019-- Brink Biologics, Inc. , a NantKwest, Inc.
CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 6, 2019-- NantKwest ( Nasdaq:NK ) today announced the appointment of Cheryl L. Cohen to the Board of Directors of NantKwest , effective immediately. “Cheryl is a proven business executive and highly experienced board member in both the biotechnology and
SAN DIEGO (December 24, 2014) —Conkwest, Inc., the N atural K iller Cell Co mpany of the West, developing the proprietary Natural Killer (NK) cell-line platform, Neukoplast ® as an immuno-oncology therapeutic, announces that Dr. Patrick Soon-Shiong, NantWorks founder, physician scientist and
SAN DIEGO (December 29, 2014) – Conkwest, Inc. (the Natural Killer Cell Company of the West), an immuno-oncology company developing Neukoplast ® , a proprietary Natural Killer (NK) cell-line based therapy, announces the appointments of Robert Rosen and Henry Ji, Ph.D.
CARDIFF-BY-THE-SEA, Calif.--( BUSINESS WIRE )--Conkwest, Inc., a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases, today announced that it has publicly
SAN DIEGO , Jan. 6, 2015 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE ; Sorrento), an oncology company developing new treatments for cancer and Conkwest, Inc., an immuno-oncology company developing proprietary Neukoplast ® , a Natural Killer (NK) cell-line based therapy, announced
CBR to Provide Umbilical Cord-Derived Cellular Material to NantKwest for additional COVID-19 Clinical Trials Utilizing MSC Therapy Los Angeles, Calif., and El Segundo, Calif., August 10, 2020 – CBR® by Generate Life Sciences, the world’s largest private newborn stem cell bank, and NantKwest
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 22, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory